Skip to content
Business Segments · Antitrust legal settlements

North American Pharmaceutical — Antitrust legal settlements

McKesson North American Pharmaceutical — Antitrust legal settlements remained flat by 0.0% to $5.75M in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 61.7%, from $15M to $5.75M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ4 2026May 8, 2026

How to read this metric

An increase represents higher legal risk and potential negative impact on segment margins, while a decrease suggests a reduction in litigation-related liabilities.

Detailed definition

This metric tracks the financial impact of legal settlements specifically related to antitrust litigation within the Nor...

Peer comparison

Commonly reported by major pharmaceutical wholesalers who face systemic industry litigation, comparable to peers in the 'Big Three' wholesalers.

Metric ID: mck_segment_north_american_pharmaceutical_antitrust_legal_settlements

Historical Data

8 periods
 Q3 '24Q4 '24Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Value$63M$31M$0$15M$5.75M$5.75M$5.75M$5.75M
QoQ Change-50.8%-100.0%-61.7%+0.0%+0.0%+0.0%
YoY Change-100.0%-51.6%-61.7%
Range$0$63M
CAGR-74.5%
Avg YoY Growth-71.1%
Median YoY Growth-61.7%
Current Streak3 quarters growth

Frequently Asked Questions

What is McKesson's north american pharmaceutical — antitrust legal settlements?
McKesson (MCK) reported north american pharmaceutical — antitrust legal settlements of $5.75M in Q4 2026.
How has McKesson's north american pharmaceutical — antitrust legal settlements changed year-over-year?
McKesson's north american pharmaceutical — antitrust legal settlements decreased by 61.7% year-over-year, from $15M to $5.75M.
What does north american pharmaceutical — antitrust legal settlements mean?
Financial costs incurred from legal settlements related to antitrust issues within the North American Pharmaceutical segment.